Sort   by:  
 Page size 
Alzheimer's disease causes a progressive dementia that currently affects over 35 million individuals worldwide and is expected to affect 115 million by 2050 (ref. 1). There are no cures or disease-modifying therapies, and this may be due to our inability to detect the disease before it has progresse...
2014-03-09 | MTBLS72 | MetaboLights
Hippocampal gene expression profiling in scopolamine treated adult rats following stimulation in a spatial memory task
ORGANISM(S): Rattus norvegicus 
Here, we present findings from a drug discovery program aimed at developing small molecules that enhance brain sCLU levels and assessed their impact on AD pathology and cognition. A high-throughput screening campaign identified two classes of epigenetic modulators to increase sCLU levels, and medici...
ORGANISM(S): Mus musculus (Mouse) 
2026-03-30 | PXD060171 | Pride
FTY720/Fingolimod, an FDA-approved drug for treatment of multiple sclerosis, has beneficial effects in the CNS that are not yet well understood, independent of its effects on immune cell trafficking. Here we show that FTY720 enters the nucleus where it is phosphorylated by sphingosine kinase 2 (SphK...
ORGANISM(S): Mus musculus 
A prevalent view in treating age-dependent disorders including Alzheimer’s disease (AD) is that the underlying amyloid plaque pathology must be targeted for cognitive improvements. In contrast, we report here that repeated scanning ultrasound (SUS) treatment at 1 MHz frequency can ameliorate memory ...
ORGANISM(S): Mus musculus (Mouse) 
2024-03-19 | PXD050248 | Pride
Sort   by:  
 Page size